Protease inhibitor resistance in HIV-infected patients: Molecular and clinical perspectives

Antiviral Research

Volumn 76, Issue 3, 2007, Pages 203-221

  Martinez Cajas, Jorge L ^a   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cross resistance; Genetic barrier; HIV; Mutations; Protease inhibitors; Salvage therapy

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; CYTOCHROME P450; DARUNAVIR; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR; TIPRANAVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG POTENTIATION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 35348992176     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2007.06.010     Document Type: Review

References (196)

1. Abecasis A.B., Deforche K., Bacheler L.T., McKenna P., Carvalho A.P., Gomes P., Vandamme A.M., and Camacho R.J. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir. Ther. 11 (2006) 581-589
2. Acosta E.P. Pharmacokinetic enhancement of protease inhibitors. J. Acquir. Immune Defic. Syndr. 29 Suppl. 1 (2002) S11-S18
3. Acosta E.P., Bardeguez A., Zorrilla C.D., Van Dyke R., Hughes M.D., Huang S., Pompeo L., Stek A.M., Pitt J., Watts D.H., Smith E., Jimenez E., and Mofenson L. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. 48 (2004) 430-436
4. Ammassari A., Murri R., Pezzotti P., Trotta M.P., Ravasio L., De Longis P., Lo Caputo S., Narciso P., Pauluzzi S., Carosi G., Nappa S., Piano P., Izzo C.M., Lichtner M., Rezza G., Monforte A., Ippolito G., d'Arminio Moroni M., Wu A.W., and Antinori A. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J. Acquir. Immune Defic. Syndr. 28 (2001) 445-449
5. Ananworanich J., Hill A., Siangphoe U., Ruxrungtham K., Prasithsirikul W., Chetchotisakd P., Kiertiburanakul S., Munsakul W., Raksakulkarn P., Tansuphasawadikul S., Nuesch R., Cooper D.A., and Hirschel B. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir. Ther. 10 (2005) 761-767
6. Ananworanich J., Hirschel B., Sirivichayakul S., Ubolyam S., Jupimai T., Prasithsirikul W., Chetchotisakd P., Kiertiburanakul S., Munsakul W., Raksakulkarn P., Tansuphasawadikul S., Schutz M., Snowden W., and Ruxrungtham K. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir. Antivir. Ther. 11 (2006) 631-635
7. Antinori A., Trotta M., Lorenzini P., Carosi G., Gianotti N., Maggiolo F., Torti C., Castagna A., Andreoni M., and Perno C. The role of thymidine analogues in rescue therapy in patients carrying K65R mutation. Antivir. Ther. 11 (2006) S93
8. Bachmeier C.J., Spitzenberger T.J., Elmquist W.F., and Miller D.W. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm. Res. 22 (2005) 1259-1268
9. Badri S.M., Adeyemi O.M., Max B.E., Zagorski B.M., and Barker D.E. How does expert advice impact genotypic resistance testing in clinical practice?. Clin. Infect. Dis. 37 (2003) 708-713
10. Baldwin J.R., Boron M.T., Wang Y., Schneck D.W., and Hopkins N.K. Effects of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA (1998)
11. Bangsberg D.R., Acosta E.P., Gupta R., Guzman D., Riley E.D., Harrigan P.R., Parkin N., and Deeks S.G. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20 (2006) 223-231
12. Bangsberg D.R., Charlebois E.D., Grant R.M., Holodniy M., Deeks S.G., Perry S., Conroy K.N., Clark R., Guzman D., Zolopa A., and Moss A. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17 (2003) 1925-1932
13. Bangsberg D.R., Moss A.R., and Deeks S.G. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J. Antimicrob. Chemother. 53 (2004) 696-699
14. Bangsberg D.R., Porco T.C., Kagay C., Charlebois E.D., Deeks S.G., Guzman D., Clark R., and Moss A. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J. Infect. Dis. 190 (2004) 162-165
15. Barbour J.D., Hecht F.M., Wrin T., Liegler T.J., Ramstead C.A., Busch M.P., Segal M.R., Petropoulos C.J., and Grant R.M. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 18 (2004) 1683-1689
16. Baxter J.D., Schapiro J.M., Boucher C.A., Kohlbrenner V.M., Hall D.B., Scherer J.R., and Mayers D.L. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J. Virol. 80 (2006) 10794-10801
17. Bossi P., Peytavin G., Ait-Mohand H., Delaugerre C., Ktorza N., Paris L., Bonmarchand M., Cacace R., David D.J., Simon A., Lamotte C., Marcelin A.G., Calvez V., Bricaire F., Costagliola D., and Katlama C. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. 5 (2004) 352-359
18. Brenner B., Routy J.P., Quan Y., Moisi D., Oliveira M., Turner D., and Wainberg M.A. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS 18 (2004) 1653-1660
19. Brumme Z.L., Dong W.W., Chan K.J., Hogg R.S., Montaner J.S., O'Shaughnessy M.V., and Harrigan P.R. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 17 (2003) 201-208
20. Calza L., Manfredi R., and Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J. Antimicrob. Chemother. 53 (2004) 10-14
21. Carrillo A., Stewart K.D., Sham H.L., Norbeck D.W., Kohlbrenner W.E., Leonard J.M., Kempf D.J., and Molla A. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. 72 (1998) 7532-7541
22. 50) as predictor of virological response. AIDS 17 (2003) 262-264
23. Castagna A., Gianotti N., Galli L., Danise A., Hasson H., Boeri E., Hoetelmans R., Nauwelaers D., and Lazzarin A. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen. Antivir. Ther. 9 (2004) 537-543
24. Charpentier C., Lecossier D., Clavel F., and Hance A. Role of resistance and fitness in driving the evolution of the protease in patients failing treatment with protease inhibitors. Abstr. 10th Conf Retrovir Oppor Infect, vol. 10. Boston, MA, USA, February 10-14 (2003) (abstract no. 601)
25. Choo E.F., Leake B., Wandel C., Imamura H., Wood A.J., Wilkinson G.R., and Kim R.B. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28 (2000) 655-660
26. Clemente J.C., Hemrajani R., Blum L.E., Goodenow M.M., and Dunn B.M. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. Biochemistry 42 (2003) 15029-15035
27. Clevenbergh P., Bozonnat M.C., Kirstetter M., Durant J., Cua E., del Giudice P., Montagne N., and Simonet P. Variable virological outcomes according to the center providing antiretroviral therapy within the PharmAdapt clinical trial. HIV Clin. Trials 4 (2003) 84-91
28. Clotet B., Ruiz L., Martinez-Picado J., Negredo E., Hill A., and Popescu M. Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts. HIV Clin. Trials 3 (2002) 316-323
29. Coakley E., Mass M., Chappey C., and Parkin N. Atazanavir (ATV) resistance in a protease inhibitor naive patient treated with ATV/ritonavir associated with development of high-level ATV resistance and the N88S mutation in protease. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA (2005) (abstract 716)
30. Coffin J.M. HIV pathogenesis. Lines drawn in epitope wars. Nature 375 (1995) 534-535
31. Cohen C.J. Ritonavir-boosted protease inhibitors, Part 1: strategies for balancing efficacy with effects on lipids. AIDS Read 15 (2005) 462-465 470-471, 474, 477
32. Colonno R., Rose R., McLaren C., Thiry A., Parkin N., and Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J. Infect Dis. 189 (2004) 1802-1810
33. Colonno R.J., Thiry A., Limoli K., and Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob. Agents Chemother. 47 (2003) 1324-1333
34. Condra J.H., Holder D.J., Schleif W.A., Blahy O.M., Danovich R.M., Gabryelski L.J., Graham D.J., Laird D., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Yang T., Chodakewitz J.A., Deutsch P.J., Leavitt R.Y., Massari F.E., Mellors J.W., Squires K.E., Steigbigel R.T., Teppler H., and Emini E.A. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70 (1996) 8270-8276
35. Condra J.H., Petropoulos C.J., Ziermann R., Schleif W.A., Shivaprakash M., and Emini E.A. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J. Infect. Dis. 182 (2000) 758-765
36. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374 (1995) 569-571
37. Conradie F., Sanne I., Venter W., and Eron J. Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. AIDS 18 (2004) 1084-1085
38. Craig J.C., Duncan I.B., Hockley D., Grief C., Roberts N.A., and Mills J.S. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res. 16 (1991) 295-305
39. da Silveira V.L., Drachler Mde L., Leite J.C., and Pinheiro C.A. Characteristics of HIV antiretroviral regimen and treatment adherence. Braz. J. Infect. Dis. 7 (2003) 194-201
40. De Luca A., Cingolani A., Di Giambenedetto S., Trotta M.P., Baldini F., Rizzo M.G., Bertoli A., Liuzzi G., Narciso P., Murri R., Ammassari A., Perno C.F., and Antinori A. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J. Infect. Dis. 187 (2003) 1934-1943
41. de Mendoza C., Valer L., Bacheler L., Pattery T., Corral A., and Soriano V. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. AIDS 20 (2006) 1071-1074
42. De Meyer S., Vangeneugden T., Lefebvre E., Azijn H., De Baere I., Van Baelen B., and de Béthune M.-P. Phenotypic and genotypic determinants of resistance to TMC114: pooled analysis of POWER 1, 2 and 3. XV International Drug Resistance Workshop. Sitges, Spain (2006) (abstract 73)
43. Deeks S.G., Hecht F.M., Swanson M., Elbeik T., Loftus R., Cohen P.T., and Grant R.M. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 13 (1999) F35-F43
44. DeGruttola V., Dix L., D'Aquila R., Holder D., Phillips A., Ait-Khaled M., Baxter J., Clevenbergh P., Hammer S., Harrigan R., Katzenstein D., Lanier R., Miller M., Para M., Yerly S., Zolopa A., Murray J., Patick A., Miller V., Castillo S., Pedneault L., and Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 5 (2000) 41-48
45. Descamps D., Flandre P., Calvez V., Peytavin G., Meiffredy V., Collin G., Delaugerre C., Robert-Delmas S., Bazin B., Aboulker J.P., Pialoux G., Raffi F., and Brun-Vezinet F. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 283 (2000) 205-211
46. Doyon L., Croteau G., Thibeault D., Poulin F., Pilote L., and Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70 (1996) 3763-3769
47. Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., Montagne N., Boucher C.A., Schapiro J.M., and Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353 (1999) 2195-2199
48. Dykes C., Najjar J., Bosch R.J., Wantman M., Furtado M., Hart S., Hammer S.M., and Demeter L.M. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. J. Infect. Dis. 189 (2004) 1091-1096
49. Elbeik T., Hoo B.S., Campodonico M.E., Dileanis J., Fay F.F., Bortolozzi R.L., Benetti M.S., Fay O.H., Marlowe N., Petrauskene O., Chernoff D., Smith L., and Ng V.L. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy. J. Hum. Virol. 4 (2001) 317-328
50. Ergun-Longmire B., Lin-Su K., Dunn A.M., Chan L., Ham K., Sison C., Stavola J., and Vogiatzi M.G. Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus. Endocr. Pract. 12 (2006) 514-521
51. Erickson J.W., Gulnik S.V., and Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 13 Suppl. A (1999) S189-S204
52. Falcoz C., Jenkins J.M., Bye C., Hardman T.C., Kenney K.B., Studenberg S., Fuder H., and Prince W.T. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J. Clin. Pharmacol. 42 (2002) 887-898
53. Fellay J., Marzolini C., Meaden E.R., Back D.J., Buclin T., Chave J.P., Decosterd L.A., Furrer H., Opravil M., Pantaleo G., Retelska D., Ruiz L., Schinkel A.H., Vernazza P., Eap C.B., and Telenti A. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359 (2002) 30-36
54. Ferrer E., Podzamczer D., Arnedo M., Fumero E., McKenna P., Rinehart A., Perez J.L., Barbera M.J., Pumarola T., Gatell J.M., and Gudiol F. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine. J. Infect. Dis. 187 (2003) 687-690
55. Flexner C. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 649-674
56. Flys T.S., Mwatha A., Donnell D., Nakabiito C., Musoke P., Mmiro F., Jackson J.B., Guay L.A., and Eshleman S.H. Fading of K103N-containing HIV-1 variants after initial and repeated exposure to single dose nevirapine for prevention of HIV-1 mother-to-child transmission (HIVNET 012). Abstracts of the XV International Drug Resistance Workshop. Sitges, Spain, June 13-17 (2006) (abstract 45)
57. Ford J., Khoo S.H., and Back D.J. The intracellular pharmacology of antiretroviral protease inhibitors. J. Antimicrob. Chemother. 54 (2004) 982-990
58. Friedland G.H., and Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 13 Suppl. 1 (1999) S61-S72
59. Friend J., Parkin N., Liegler T., Martin J.N., and Deeks S.G. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 18 (2004) 1965-1966
60. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Office of AIDS Research Advisory Council. AIDS Info/US Department of Health and Human Services, 2006.
61. Gatanaga H., Suzuki Y., Tsang H., Yoshimura K., Kavlick M.F., Nagashima K., Gorelick R.J., Mardy S., Tang C., Summers M.F., and Mitsuya H. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J. Biol. Chem. 277 (2002) 5952-5961
62. Gathe Jr. J.C., Wood R., Sanne I., DeJesus E., Schurmann D., Gladysz A., Garris C., Givens N., Elston R., and Yeo J. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Clin. Ther. 28 (2006) 745-754
63. Ghosn J., Pellegrin I., Goujard C., Deveau C., Viard J.P., Galimand J., Harzic M., Tamalet C., Meyer L., Rouzioux C., and Chaix M.L. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 20 (2006) 159-170
64. Gianotti N., Mondino V., Rossi M.C., Chiesa E., Mezzaroma I., Ladisa N., Guaraldi G., Torti C., Tarquini P., Castelli P., Di Carlo A., Boeri E., Keulen W., Kenna P.M., and Lazzarin A. Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study. Clin. Infect. Dis. 42 (2006) 1470-1480
65. Gonzalez de Requena D., Gallego O., Valer L., Jimenez-Nacher I., and Soriano V. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res. Hum. Retroviruses 20 (2004) 275-278
66. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62 (1993) 385-427
67. Graham N., Peeters M., Verbiest W., Harrigan R., and Larder B. The virtual phenotype is an independent predictor of clinical response. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, USA, February 4-8 (2001) (abstract 524)
68. Gross R., Yip B., Wood E., Bangsberg D., Justice A., Montaner J., and Hogg R. Boosted PI are more forgiving of suboptimal adherence than non-boosted PI or NNRT. 13th Conference on Retroviruses and Opportunistic Infections. Denver, Colorado (2006)
69. Grossman Z., Paxinos E.E., Averbuch D., Maayan S., Parkin N.T., Engelhard D., Lorber M., Istomin V., Shaked Y., Mendelson E., Ram D., Petropoulos C.J., and Schapiro J.M. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob. Agents Chemother. 48 (2004) 2159-2165
70. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Richman D.D., Valentine F.T., Jonas L., Meibohm A., Emini E.A., and Chodakewitz J.A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337 (1997) 734-739
71. Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron Jr. J.J., Feinberg J.E., Balfour Jr. H.H., Deyton L.R., Chodakewitz J.A., and Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337 (1997) 725-733
72. Hare C.B., Mellors J., Krambrink A., Su Z., Skiest D., Margolis D., Patel S., Barnas D., Frenkel L., Coombs R., Aweeka F., Morse G., Haas D., Kim R., Boltz V., Palmer S., Coffin J., and Havlir D. Selection of NNRTI-resistant HIV-1 after discontinuation of a virologically suppressive regimen. Abstracts of the XV International Drug Resistance Workshop. Sitges, Spain (2006) (abstract 34)
73. Harrigan P.R., Hogg R.S., Dong W.W., Yip B., Wynhoven B., Woodward J., Brumme C.J., Brumme Z.L., Mo T., Alexander C.S., and Montaner J.S. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J. Infect. Dis. 191 (2005) 339-347
74. Harzic M., Pellegrin I., Deveau C., Chaix M.L., Dubeaux B., Garrigue I., Ngo N., Rouzioux C., Goujard C., Hoen B., Sereni D., Delfraissy J.F., and Meyer L. Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment. AIDS 16 (2002) 793-796
75. Havlir D.V., Hellmann N.S., Petropoulos C.J., Whitcomb J.M., Collier A.C., Hirsch M.S., Tebas P., Sommadossi J.P., and Richman D.D. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 283 (2000) 229-234
76. Hicks C.B., Cahn P., Cooper D.A., Walmsley S.L., Katlama C., Clotet B., Lazzarin A., Johnson M.A., Neubacher D., Mayers D., and Valdez H. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368 (2006) 466-475
77. Hirsch M.S., Conway B., D'Aquila R.T., Johnson V.A., Brun-Vezinet F., Clotet B., Demeter L.M., Hammer S.M., Jacobsen D.M., Kuritzkes D.R., Loveday C., Mellors J.W., Vella S., and Richman D.D. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 279 (1998) 1984-1991
78. Hoetelmans R.M. Pharmacology of antiretroviral drugs. Antivir. Ther. 4 Suppl. 3 (1999) 29-41
79. Holguin A., Paxinos E., Hertogs K., Womac C., and Soriano V. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J. Clin. Virol. 31 (2004) 215-220
80. Hu W.S., and Temin H.M. Retroviral recombination and reverse transcription. Science 250 (1990) 1227-1233
81. Hunt P.W., Deeks S.G., Rodriguez B., Valdez H., Shade S.B., Abrams D.I., Kitahata M.M., Krone M., Neilands T.B., Brand R.J., Lederman M.M., and Martin J.N. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17 (2003) 1907-1915
82. Ives K.J., Jacobsen H., Galpin S.A., Garaev M., Dorrell L., Mous J., Bragman K., and Weber J.N. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. J. Antimicrob. Chemother. 39 (1997) 771-779
83. Jacobsen H., Yasargil K., Winslow D.L., Craig J.C., Krohn A., Duncan I.B., and Mous J. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206 (1995) 527-534
84. Janneh O., Owen A., Chandler B., Hartkoorn R.C., Hart C.A., Bray P.G., Ward S.A., Back D.J., and Khoo S.H. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 19 (2005) 2097-2102
85. Johnson J.A., Li J.-F., Wei X., Craig C., Stone C., Horton J.H., Lanier E.R., and Heneine W. Baseline detection of low-frequency drug resistance-associated mutations is strongly associated with virological failure in previously antiretroviral-naive HIV-1-infected patients. Abstracts of the XV International Drug Resistance Workshop. Sitges, Spain (2006) (abstract 69)
86. Johnson V.A., Brun-Vezinet F., Clotet B., Kuritzkes D.R., Pillay D., Schapiro J.M., and Richman D.D. Update of the drug resistance mutations in HIV-1. Top. HIV Med. 14 Fall (2006) 125-130
87. Juliano R.L., and Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455 (1976) 152-162
88. Kaufmann D., Pantaleo G., Sudre P., and Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 351 (1998) 723-724
89. Kempf D.J., Isaacson J.D., King M.S., Brun S.C., Xu Y., Real K., Bernstein B.M., Japour A.J., Sun E., and Rode R.A. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75 (2001) 7462-7469
90. Kempf D.J., Marsh K.C., Kumar G., Rodrigues A.D., Denissen J.F., McDonald E., Kukulka M.J., Hsu A., Granneman G.R., Baroldi P.A., Sun E., Pizzuti D., Plattner J.J., Norbeck D.W., and Leonard J.M. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41 (1997) 654-660
91. King J.R., Wynn H., Brundage R., and Acosta E.P. Pharmacokinetic enhancement of protease inhibitor therapy. Clin. Pharmacokinet. 43 (2004) 291-310
92. King M.S., Brun S.C., and Kempf D.J. Relationship between adherence and the development of resistance in antiretroviral-naive. HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. J. Infect. Dis. 191 (2005) 2046-2052
93. Knobel H., Escobar I., Polo R., Ortega L., Martin-Conde M.T., Casado J.L., Codina C., Fernandez J., Galindo M.J., Ibarra O., Llinas M., Miralles C., Riera M., Fumaz C.R., Segador A., Segura F., and Chamorro L. [Recommendations from GESIDA/SEFH/PNS to improve adherence to antiviral treatment (2004)]. Enferm. Infect. Microbiol. Clin. 23 (2005) 221-231
94. Krishna R., and Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11 (2000) 265-283
95. Larder B.A., Kemp S.D., and Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (VirtualPhenotype). Antiviral Ther. 5 Suppl. 3 (2000) 49 (abstract 63)
96. Larder B.A., Hertogs K., Bloor S., van den Eynde C.H., DeCian W., Wang Y., Freimuth W.W., and Tarpley G. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 14 (2000) 1943-1948
97. Ledergerber B., Egger M., Opravil M., Telenti A., Hirschel B., Battegay M., Vernazza P., Sudre P., Flepp M., Furrer H., Francioli P., and Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 353 (1999) 863-868
98. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., Koup R.A., Mellors J.W., Connick E., Conway B., Kilby M., Wang L., Whitcomb J.M., Hellmann N.S., and Richman D.D. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347 (2002) 385-394
99. Logsdon B.C., Vickrey J.F., Martin P., Proteasa G., Koepke J.I., Terlecky S.R., Wawrzak Z., Winters M.A., Merigan T.C., and Kovari L.C. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. J. Virol. 78 (2004) 3123-3132
100. Lucas G.M., Chaisson R.E., and Moore R.D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131 (1999) 81-87
101. Luque I., and Freire E. Structural parameterization of the binding enthalpy of small ligands. Proteins 49 (2002) 181-190
102. Luque I., and Freire E. Structure-based prediction of binding affinities and molecular design of peptide ligands. Methods Enzymol. 295 (1998) 100-127
103. Macmanus S., Yates P., White S., Richards N., and Snowden W. GW433908 in ART-naive subjects: absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen. 10th Conf Retrovir Oppor Infect. Boston, MA, USA, February 10-14 (2003) (abstract no. 598)
104. Maggiolo F., Ravasio L., Ripamonti D., Gregis G., Quinzan G., Arici C., Airoldi M., and Suter F. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin. Infect. Dis. 40 (2005) 158-163
105. Maguire M.F., Guinea R., Griffin P., Macmanus S., Elston R.C., Wolfram J., Richards N., Hanlon M.H., Porter D.J., Wrin T., Parkin N., Tisdale M., Furfine E., Petropoulos C., Snowden B.W., and Kleim J.P. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 76 (2002) 7398-7406
106. Maguire M., Shortino D., Klein A., Harris W., Manohitharajah V., Tisdale M., Elston R., Yeo J., Randall S., Xu F., Parker H., May J., and Snowden W. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob. Agents Chemother. 46 (2002) 731-738
107. Marcelin A.G., Cohen-Codar I., King M.S., Colson P., Guillevic E., Descamps D., Lamotte C., Schneider V., Ritter J., Segondy M., Peigue-Lafeuille H., Morand-Joubert L., Schmuck A., Ruffault A., Palmer P., Chaix M.L., Mackiewicz V., Brodard V., Izopet J., Cottalorda J., Kohli E., Chauvin J.P., Kempf D.J., Peytavin G., and Calvez V. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 49 (2005) 1720-1726
108. Marcelin A.G., Masquelier B., Descamps D., Izopet J., Charpentier C., Alloui C., Peytavin G., Lavignon M., Flandre P., and Calvez V. Mutations associated with response to boosted tipranavir in HIV-1-infected PI-experienced patients. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA (2007) (abstract no. 612)
109. Marcelin A.G., Lamotte C., Delaugerre C., Ktorza N., Ait Mohand H., Cacace R., Bonmarchand M., Wirden M., Simon A., Bossi P., Bricaire F., Costagliola D., Katlama C., Peytavin G., and Calvez V. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 47 (2003) 594-600
110. Markowitz M., Mohri H., Mehandru S., Shet A., Berry L., Kalyanaraman R., Kim A., Chung C., Jean-Pierre P., Horowitz A., La Mar M., Wrin T., Parkin N., Poles M., Petropoulos C., Mullen M., Boden D., and Ho D.D. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 365 (2005) 1031-1038
111. Martin P., Vickrey J.F., Proteasa G., Jimenez Y.L., Wawrzak Z., Winters M.A., Merigan T.C., and Kovari L.C. "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target. Structure 13 (2005) 1887-1895
112. Martinez-Picado J., Savara A.V., Sutton L., and D'Aquila R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73 (1999) 3744-3752
113. Martinez E., and Gatell J.M. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: the lipodystrophy syndrome. Curr. Opin. Infect. Dis. 12 (1999) 13-19
114. Martinez J.L., McArthur R., VIckrey J., Martin P., Proteasa G., Kondapalli K., Jimenez Y., Wawrzak W., Winters M., Merigan T., and Kovari L. The multi-drug resistance protease represents a novel drug target. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (2004), American Society of Microbiology, Washington, DC, USA
115. Masquelier B., Breilh D., Neau D., Lawson-Ayayi S., Lavignolle V., Ragnaud J.M., Dupon M., Morlat P., Dabis F., and Fleury H. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 46 (2002) 2926-2932
116. Mazzotta F., Lo Caputo S., Torti C., Tinelli C., Pierotti P., Castelli F., Lazzarin A., Angarano G., Maserati R., Gianotti N., Ladisa N., Quiros-Roldan E., Rinehart A.R., and Carosi G. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J. Acquir. Immune Defic. Syndr. 32 (2003) 268-280
117. McCallister S., Valdez H., Curry K., MacGregor T., Borin M., Freimuth W., Wang Y., and Mayers D.L. A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease
118. McGrath D., Hammond J., Frederick D., Mathew M., Kastango K., and McLaren C. Evaluation of resistance patterns in treatment-naive subjects with virological failure on atazanavir- or atazanavir/ritonavir-containing regimens. Antivir. Ther. 11 (2006) S97 (abstract 87)
119. Mo H., King M.S., King K., Molla A., Brun S., and Kempf D.J. Selection of resistance in protease inhibitor-experienced. Human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J. Virol. 79 (2005) 3329-3338
120. Mocroft A., Ruiz L., Reiss P., Ledergerber B., Katlama C., Lazzarin A., Goebel F.D., Phillips A.N., Clotet B., and Lundgren J.D. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 17 (2003) 1741-1751
121. Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P.J., Mo H.M., Markowitz M., Chernyavskiy T., Niu P., Lyons N., Hsu A., Granneman G.R., Ho D.D., Boucher C.A., Leonard J.M., Norbeck D.W., and Kempf D.J. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2 (1996) 760-766
122. Montes M.L., Pulido F., Barros C., Condes E., Rubio R., Cepeda C., Dronda F., Antela A., Sanz J., Navas E., Miralles P., Berenguer J., Perez S., Zapata A., Gonzalez-Garcia J.J., Pena J.M., Vazquez J.J., and Arribas J.R. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J. Antimicrob. Chemother. 55 (2005) 800-804
123. Moyle G.J., and Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. 2 (2001) 105-113
124. Myint L., Matsuda M., Matsuda Z., Yokomaku Y., Chiba T., Okano A., Yamada K., and Sugiura W. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48 (2004) 444-452
125. Naeger L.K., and Struble K.A. Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. AIDS 21 (2007) 179-185
126. Noble S., and Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52 (1996) 93-112
127. Ntemgwa M., Brenner B.G., Oliveira M., Moisi D., and Wainberg M.A. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob. Agents Chemother. 51 (2007) 604-610
128. Ode H., Ota M., Neya S., Hata M., Sugiura W., and Hoshino T. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases. J. Phys. Chem. B 109 (2005) 565-574
129. Ogden R., and Flexner C. Protease Inhibitors in AIDS Therapy. first ed. vol. 1 (2001), Marcel Dekker, AG, New York
130. Ohtaka H., Muzammil S., Schon A., Velazquez-Campoy A., Vega S., and Freire E. Thermodynamic rules for the design of high affinity HIV-1 protease inhibitors with adaptability to mutations and high selectivity towards unwanted targets. Int. J. Biochem. Cell Biol. 36 (2004) 1787-1799
131. Ohtaka H., Velazquez-Campoy A., Xie D., and Freire E. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci. 11 (2002) 1908-1916
132. Ormaasen V., Sandvik L., Asjo B., Holberg-Petersen M., Gaarder P.I., and Bruun J.N. An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy. HIV Med. 5 (2004) 400-406
133. Palmer S., King M., Wiegand A., Maldarelli F., Bernstein B., Hanna G., Brun S., Kempf D., Mellors J., and Coffin J. Low-level viremia for at least 7 years in patients on suppressive antiretroviral therapy. Abstracts of the XV International Drug Resistance Workshop. Sitges, Spain, June 13-17 (2006) (abstract 55)
134. Panidou E.T., Trikalinos T.A., and Ioannidis J.P. Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis. AIDS 18 (2004) 2153-2161
135. Park S., and Sinko P.J. P-glycoprotein and multidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J. Pharmacol. Exp. Ther. 312 (2005) 1249-1256
136. Parkin N., and Chappey C. Protease mutations associated with higher or lower than expected tipranavir (TPV) susceptibility based on the TPV mutation score. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, February 5-8 (2006) (abstract 537)
137. Parkin N.T., Chappey C., and Petropoulos C.J. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 17 (2003) 955-961
138. Partaledis J.A., Yamaguchi K., Tisdale M., Blair E.E., Falcione C., Maschera B., Myers R.E., Pazhanisamy S., Futer O., Cullinan A.B., et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69 (1995) 5228-5235
139. Paterson D.L., Swindells S., Mohr J., Brester M., Vergis E.N., Squier C., Wagener M.M., and Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133 (2000) 21-30
140. Patick A.K., Duran M., Cao Y., Shugarts D., Keller M.R., Mazabel E., Knowles M., Chapman S., Kuritzkes D.R., and Markowitz M. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42 (1998) 2637-2644
141. Pazhanisamy S., Stuver C.M., Cullinan A.B., Margolin N., Rao B.G., and Livingston D.J. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J. Biol. Chem. 271 (1996) 17979-17985
142. Petersen J.L., and McGuire D.K. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management. Diab. Vasc. Dis. Res. 2 (2005) 9-15
143. Piliero P.J., Narkin N., and Mayers D. Impact of protease mutations L33F/I, V82A, I84V, and L90M on ritonavir-boosted protease inhibitor susceptibility. 46th ICAAC. San Francisco, September 27-30 (2006) (abstract H-998)
144. Piliero P.J. Atazanavir: a novel HIV-1 protease inhibitor. Expert Opin. Investig. Drugs 11 (2002) 1295-1301
145. Poppe S.M., Slade D.E., Chong K.T., Hinshaw R.R., Pagano P.J., Markowitz M., Ho D.D., Mo H., Gorman III R.R., Dueweke T.J., Thaisrivongs S., and Tarpley W.G. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 41 (1997) 1058-1063
146. Preston B.D., Poiesz B.J., and Loeb L.A. Fidelity of HIV-1 reverse transcriptase. Science 242 (1988) 1168-1171
147. Quinones-Mateu M.E., and Arts E.J. Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Updat. 5 (2002) 224-233
148. Race E., Gilbert S.M., Sheldon J.G., Rose J.S., Moffatt A.R., Sitbon G., Dissanayeke S.R., Cammack N., and Duncan I.B. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy. AIDS 12 (1998) 1465-1474
149. Rathbun R.C., and Rossi D.R. Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann. Pharmacother. 36 (2002) 702-706
150. Resch W., Ziermann R., Parkin N., Gamarnik A., and Swanstrom R. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J. Virol. 76 (2002) 8659-8666
151. Riddler S., et al. A prospective, randomized, phase III trial of NRTI-, PI- and NNRTI-sparing regimens for initial treatment of HIV-1 infection-ACTG 5142. Program and abstracts of the XVI International AIDS Conference. Toronto, Canada, August 13-18 (2006) (abstract THLB0204)
152. Robinson B.S., Riccardi K.A., Gong Y.F., Guo Q., Stock D.A., Blair W.S., Terry B.J., Deminie C.A., Djang F., Colonno R.J., and Lin P.F. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob. Agents Chemother. 44 (2000) 2093-2099
153. Rodes B., Toro C., Sheldon J.A., Jimenez V., Mansinho K., and Soriano V. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS 20 (2006) 127-129
154. Rodriguez Novoa S., Barreiro P., Rendon A., Barrios A., Corral A., Jimenez-Nacher I., Gonzalez-Lahoz J., and Soriano V. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C → T polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis. 42 (2006) 291-295
155. Roge B.T., Barfod T.S., Kirk O., Katzenstein T.L., Obel N., Nielsen H., Pedersen C., Mathiesen L.R., Lundgren J.D., and Gerstoft J. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med. 5 (2004) 344-351
156. Rotger M., Taffe P., Bleiber G., Gunthard H.F., Furrer H., Vernazza P., Drechsler H., Bernasconi E., Rickenbach M., and Telenti A. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 192 (2005) 1381-1386
157. Rusconi S., La Seta Catamancio S., Citterio P., Kurtagic S., Violin M., Balotta C., Moroni M., Galli M., and d'Arminio-Monforte A. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob. Agents Chemother. 44 (2000) 1328-1332
158. Salama C., and Caplivski D. Development of atazanavir resistance mutations in a clinical setting among patients without evidence of preexisting protease mutations. Antivir. Ther. 10 (2005) S30 (abstract no. 28)
159. Saracino A., Monno L., Locaputo S., Torti C., Scudeller L., Ladisa N., Antinori A., Sighinolfi L., Chirianni A., Mazzotta F., Carosi G., and Angarano G. Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen). J. Acquir. Immune Defic. Syndr. 37 (2004) 1587-1598
160. Sax P.E., Xu F., Tisdale M., and Elston R. First report of development of resistance to boosted fosamprenavir in an ART-naive subject: virologic and clinical outcome. The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC, USA (2005)
161. Schapiro J.M., Lawrence J., Speck R., Winters M.A., Coombs R., Collier A.C., Efron B., and Merigan T.C. HIV RNA and resistance mutations to saquinavir and zidovudine in patients receiving dual versus triple combination therapy. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, IL (1998)
162. Schapiro J.M., Lawrence J., Speck R., Winters M.A., Efron B., Coombs R.W., Collier A.C., and Merigan T.C. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. J. Infect. Dis. 179 (1999) 249-253
163. Schapiro J.M., Winters M.A., Stewart F., Efron B., Norris J., Kozal M.J., and Merigan T.C. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann. Intern. Med. 124 (1996) 1039-1050
164. Schnell T., Schmidt B., Moschik G., Thein C., Paatz C., Korn K., and Walter H. Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples. AIDS 17 (2003) 1258-1261
165. Schurmann D., Elston R., Xu F., Kleinkauf N., Wunsche T., and Suttorp N. Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations. AIDS 20 (2006) 138-140
166. Sekar V., Spinosa-Guzman S., Lefebvre E., and Hoetelmans R. Clinical pharmacology of TMC114-a new HIV protease inhibitor. XVI International AIDS Society Conference. Toronto (2006). http://www.natap.org/2006/IAS/IAS_76.htm
167. Servais J., Lambert C., Fontaine E., Plesseria J.-M., Robert I., Arendt V., Staub T., Schneider F., Hemmer R., Burtonboy G., and Schmit J.-C. Variant Human Immunodeficiency Virus Type 1 Proteases and Response to Combination Therapy Including a Protease Inhibitor. Antimicrob. Agents Chemother. 45 (2001) 893-900
168. Sethi A.K., Celentano D.D., Gange S.J., Moore R.D., and Gallant J.E. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin. Infect. Dis. 37 (2003) 1112-1118
169. Sharom F.J., Yu X., and Doige C.A. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J. Biol. Chem. 268 (1993) 24197-24202
170. Shulman N., Zolopa A., Havlir D., Hsu A., Renz C., Boller C., Jiang P., Rode R., Gallant J., Race E., Kempf J., and Sun E. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob. Agents Chemother. 46 (2002) 3907-3916
171. Shuter J., Sarlo J.A., Kanmaz T.J., Rode R.A., and Zingman B.S. The "95% adherence rule" may not apply tolopinavir/ritonavir (LPV/r) based HAART regimens. Program and abstracts of the XVI International AIDS Conference. Toronto, Canada, August 13-18 (2006) (abstract TUPE0110)
172. Smit T.K., Brew B.J., Tourtellotte W., Morgello S., Gelman B.B., and Saksena N.K. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J. Virol. 78 (2004) 10133-10148
173. Sudano I., Spieker L.E., Noll F., Corti R., Weber R., and Luscher T.F. Cardiovascular disease in HIV infection. Am. Heart J. 151 (2006) 1147-1155
174. Surleraux D.L., Tahri A., Verschueren W.G., Pille G.M., de Kock H.A., Jonckers T.H., Peeters A., De Meyer S., Azijn H., Pauwels R., de Bethune M.-P., King N.M., Prabu-Jeyabalan M., Schiffer C.A., and Wigerinck P.B. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J. Med. Chem. 48 (2005) 1813-1822
175. Tang J.H., Sheffield J.S., Grimes J., McElwee B., Roberts S.W., Laibl V., McIntire D.D., and Wendel Jr. G.D. Effect of protease inhibitor therapy on glucose intolerance in pregnancy. Obstet. Gynecol. 107 (2006) 1115-1119
176. Thaisrivongs S., and Strohbach J.W. Structure-based discovery of tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers 51 (1999) 51-58
177. Thomas S.A. Anti-HIV drug distribution to the central nervous system. Curr. Pharm. Des. 10 (2004) 1313-1324
178. Torre D., and Tambini R. Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin. Trials 3 (2002) 1-8
179. Torti C., Quiros-Roldan E., Monno L., Patroni A., Saracino A., Angarano G., Tinelli C., Lo Caputo S., Tirelli V., Mazzotta F., and Carosi G. Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients. J. Med. Virol. 74 (2004) 29-33
180. Tupinambas U., Aleixo A., and Greco D. HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment. Braz. J. Infect. Dis. 9 (2005) 324-329
181. Tural C., Ruiz L., Holtzer C., Schapiro J., Viciana P., Gonzalez J., Domingo P., Boucher C., Rey-Joly C., and Clotet B. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16 (2002) 209-218
182. Vandamme A.M., Sonnerborg A., Ait-Khaled M., Albert J., Asjo B., Bacheler L., Banhegyi D., Boucher C., Brun-Vezinet F., Camacho R., Clevenbergh P., Clumeck N., Dedes N., De Luca A., Doerr H.W., Faudon J.L., Gatti G., Gerstoft J., Hall W.W., Hatzakis, Hellmann N., Horban A., Lundgren J.D., Kempf D., Miller M., Miller V., Myers T.W., Nielsen C., Opravil M., Palmisano L., Perno C.F., Phillips A., Pillay D., Pumarola T., Ruiz L., Salminen M., Schapiro J., Schmidt B., Schmit J.C., Schuurman R., Shulse E., Soriano V., Staszewski S., Vella S., Youle M., Ziermann R., and Perrin L. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir. Ther. 9 (2004) 829-848
183. Vangeneugden T., Winters B., Bacheler L., Picchio G., de Béthune M.-P., McKenna P., and Miralles D. Impact of optimised background regimen on virological response to TMC114 with low-dose ritonavir in POWER 1, 2 and 3, as measured by the phenotypic susceptibility score. 15th International HIV Drug Resistance Workshop. Sitges, Spain Back (2006) (abstract 31)
184. Velazquez-Campoy A., Muzammil S., Ohtaka H., Schon A., Vega S., and Freire E. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr. Drug Targets Infect. Disord. 3 (2003) 311-328
185. Velazquez-Campoy A., Vega S., and Freire E. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes. Biochemistry 41 (2002) 8613-8619
186. von Moltke L.L., Greenblatt D.J., Duan S.X., Daily J.P., Harmatz J.S., and Shader R.I. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J. Pharm. Sci. 87 (1998) 1184-1189
187. Vora S., Marcelin A.G., Gunthard H.F., Flandre P., Hirsch H.H., Masquelier B., Zinkernagel A., Peytavin G., Calvez V., Perrin L., and Yerly S. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS 20 (2006) 35-40
188. Weiser S.D., Guzman D., Riley E.D., Clark R., and Bangsberg D.R. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clin. Trials 5 (2004) 278-287
189. Winston A., Hales G., Amin J., Schaick E., Cooper D.A., and Emery S. The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals. AIDS 19 (2005) 1393-1399
190. Winzer R., Langmann P., Zilly M., Tollmann F., Schubert J., Klinker H., and Weissbrich B. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur. J. Med. Res. 8 (2003) 531-534
191. Witvrouw M., Pannecouque C., Switzer W.M., Folks T.M., De Clercq E., and Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 9 (2004) 57-65
192. Yasuda J.M., Miller C., Currier J.S., Forthal D.N., Kemper C.A., Beall G.N., Tilles J.G., Capparelli E.V., McCutchan J.A., and Haubrich R.H. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir. Ther. 9 (2004) 753-761
193. Yoshimura K., Kato R., Kavlick M.F., Nguyen A., Maroun V., Maeda K., Hussain K.A., Ghosh A.K., Gulnik S.V., Erickson J.W., and Mitsuya H. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J. Virol. 76 (2002) 1349-1358
194. Yu K., and Daar E.S. Dual protease inhibitor therapy in the management of the HIV-1. Expert. Opin. Pharmacother. 1 (2000) 1331-1342
195. Zhang Y.M., Imamichi H., Imamichi T., Lane H.C., Falloon J., Vasudevachari M.B., and Salzman N.P. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71 (1997) 6662-6670
196. Zolopa A., Towner W., Zurawski C., Crofoot G., Butcher D., Wang S., Maa J., and Seekins D. Resistance profile after treatment with an atazanavir-containing regimen: first interim analysis results from the IMPACT study (BMS AI424-128). XVI International AIDS Conference. Toronto, Canada, August 13-18 (2006)